SEARCH

SEARCH BY CITATION

References

  • Barbui, T., Finazzi, G., Galli, M. (1997) Clinical significance and predictive value of laboratory tests in thrombosis associated with anti-phospolipid antibodies. Annals of Italian Medicine International, 12, 7683.
  • Cabiedes, J., Cabral, A.R., Alarcon-Segovia, D. (1995) Clinical manifestations of the anti-phospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with anti-phospholipid antibodies. Journal of Rheumatology, 22, 18991906.
  • Cucurull, E., Espinoza, L.R., Mendez, E., Molina, J.F., Molina, J., Ordi-Ros, J., Gharavi, A.E. (1999) Anti-cardiolipin and anti-beta2glycoprotein-I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards. Lupus, 8, 134141.
  • D'Angelo, A., Safa, O., Crippa, L., Garlando, A., Sabbadini, M.G., Vigano′ D'Angelo, S. (1997) Relationship of lupus anti-coagulant, anti-cardiolipin, anti-beta2-GPI and antiprothrombin autoantibodies with history of thrombosis in patients with the clinical suspicion of APA-syndrome. Thrombosis and Haemostaiss, 78, 967968.
  • Forastiero, R.R., Martinuzzo, M.E., Cerrato, G.S., Kordich, L.C., Carreras, L.O. (1997) Relationship of anti-beta2-glycoprotein I and anti-prothrombin antibodies to thrombosis and pregnancy loss in patients with anti-phospholipid antibodies. Thrombosis and Haemostasis, 78, 10081014.
  • Galli, M. & Barbui, T. (1998) Prothrombin as cofactor for anti-phospholipids. Lupus, 7, S37S40.
  • Galli, M. & Barbui, T. (1999) Anti-prothrombin antibodies: detection and clinical significance in the anti-phospholipid syndrome. Blood, 93, 21492157.
  • Galli, M., Finazzi, G., Bevers, E.M., Barbui, T. (1995) Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent anti-phospholipid antibodies. Blood, 86, 617623.
  • Galli, M., Finazzi, G., Barbui, T. (1997a) Anti-phospholipid antibodies: predictive value of laboratory tests. Thrombosis and Haemostasis, 78, 7578.
  • Galli, M., Beretta, G., Daldossi, M., Bevers, E.M., Barbui, T. (1997b) Different anti-coagulant and immunological properties of anti-prothrombin antibodies in patients with anti-phospholipid antibodies. Thrombosis and Haemostasis, 77, 486491.
  • Galli, M., Ruggeri, L., Barbui, T. (1998) Differential effects of anti-beta2-glycoprotein I and anti-prothrombin antibodies on the anti-coagulant activity of activated protein C. Blood, 91, 19992004.
  • Galli, M., Finazzi, G., Norbis, F., Marziali, S., Marchioli, R., Barbui, T. (1999) The risk of thrombosis in patients with lupus anti-coagulants is predicted by their specific coagulation profile. Thrombosis and Haemosasis, 81, 695700.
  • Ginsberg, J.S., Wells, P.S., Brill-Edwards, P., Donovan, D., Moffatt, K., Johnston, M., Stevens, P., Hirsh, J. (1995) Anti-phospholipid antibodies and venous thromboembolism. Blood, 86, 36853691.
  • Greaves, M. (1999) Anti-phospholipid antibodies and thrombosis. Lancet, 353, 13481353.
  • Hanly, J.G. & Smith, S.A. (2000) Anti-beta2-glycoprotein I autoantibodies, in vitro thrombin generation, and the anti-phospholipid syndrome. Journal of Rheumatology, 27, 21522159.
  • Horbach, D.A., Van Oort, E., Donders, R.C., Derksen, R.H., De Groot, P.G. (1996) Lupus anti-coagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of anti-phospholipid antibodies. Thrombosis and Haemostasis, 76, 916924.
  • Horbach, D.A., Van Oort, E., Derksen, R.H., De Groot, P.G. (1998) The contribution of anti-prothrombin-antibodies to lupus anti-coagulant activity – discrimination between functional and non-functional anti-prothrombin-antibodies. Thrombosis and Haemostasis, 79, 790795.
  • Igarashi, M., Matsuura, E., Igarashi, Y., Nagae, H., Ichikawa, K., Triplett, D.A., Koike, T. (1996) Human beta2-glycoprotein I as an anti-cardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood, 87, 32623270.
  • Koike, T. & Matsuura, E. (1996) Anti-beta 2-glycoprotein I antibody: specificity and clinical significance. Lupus, 5, 378380.
  • Lakos, G., Kiss, E., Regeczy, N., Tarjan, P., Soltesz, P., Zeher, M., Bodolay, E., Szucs, G., Szakony, S., Sipka, S., Szegedi, G. (2000) Anti-prothrombin and anti-annexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases. Journal of Rheumatology, 27, 924929.
  • Matsuura, E., Igarashi, Y., Fujimoto, M., Ichikawa, K., Suzuki, T., Sumida, T., Yasuda, T., Koike, T. (1992) Heterogeneity of anti-cardiolipin antibodies defined by the anti-cardiolipin cofactor. Journal of Immunology, 148, 38853891.
  • Matsuura, E., Igarashi, Y., Yasuda, T., Triplett, D.A., Koike, T. (1994) Anti-cardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. Journal of Experimental Medicine, 179, 457462.
  • McNeil, H.P., Simpson, R.J., Chesterman, C.N., Krilis, S.A. (1990) Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proceedings of the National Academy of Sciences of the United States of America, 87, 41204124.
  • Munoz-Rodriguez, F.J., Reverter, J.C., Font, J., Tassies, D., Cervera, R., Espinosa, G., Carmona, F., Balasch, J., Ordinas, A., Ingelmo, M. (2000) Prevalence and clinical significance of anti-prothrombin antibodies in patients with systemic lupus erythematosus or with primary anti-phospholipid syndrome. Haematologica, 85, 632637.
  • Nojima, J., Suehisa, E., Akita, N., Toku, M., Fushimi, R., Tada, H., Kuratsune, H., Machii, T., Kitani, T., Amino, N. (1997) Risk of arterial thrombosis in patients with anti-cardiolipin antibodies and lupus anti-coagulant. British Journal of Haematology, 96, 447450.
  • Nojima, J., Suehisa, E., Kuratsune, H., Machii, T., Toku, M., Tada, H., Yamaguti, K., Koike, T., Kanakura, Y., Kitani, T., Amino, N. (1998) High prevalence of thrombocytopenia in SLE patients with a high level of anti-cardiolipin antibodies combined with lupus anti-coagulant. American Journal of Hematology, 58, 5560.DOI: 10.1002/(sici)1096-8652(199805)58:1<55::aid-ajh10>3.3.co;2-m
  • Nojima, J., Suehisa, E., Kuratsune, H., Machii, T., Koike, T., Kitani, T., Kanakura, Y., Amino, N. (1999) Platelet activation induced by combined effects of anti-cardiolipin and lupus anti-coagulant IgG antibodies in patients with systemic lupus erythematosus – possible association with thrombotic and thrombocytopenic complications. Thrombosis and Haemostasis, 81, 436441.
  • Palosuo, T., Virtamo, J., Haukka, J., Taylor, P.R., Aho, K., Puurunen, M., Vaarala, O. (1997) High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men – a nested case-control study. Thrombosis and Haemostasis, 78, 11781182.
  • Rao, L.V., Hoang, A.D., Rapaport, S.I. (1996) Mechanism and effects of the binding of lupus anti-coagulant IgG and prothrombin to surface phospholipid. Blood, 88, 41734182.
  • Roubey, R.A. (1994) Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anti-coagulants and other ‘anti-phospholipid’ autoantibodies. Blood, 84, 28542867.
  • Schulman, S., Svenungsson, E., Granqvist, S. (1998) Anti-cardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anti-coagulant therapy. Duration of Anti-coagulation Study Group. American Journal of Medicine, 104, 332338.